Does the media refer more to TTRX or ESPR?

In the previous week, Esperion Therapeutics had 1 more articles in the media than Turn Therapeutics. MarketBeat recorded 6 mentions for Esperion Therapeutics and 5 mentions for Turn Therapeutics. Esperion Therapeutics' average media sentiment score of 1.22 beat Turn Therapeutics' score of 0.48 indicating that Esperion Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Turn Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Esperion Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CYRX or TTRX?

In the previous week, Turn Therapeutics had 2 more articles in the media than CryoPort. MarketBeat recorded 5 mentions for Turn Therapeutics and 3 mentions for CryoPort. CryoPort's average media sentiment score of 1.40 beat Turn Therapeutics' score of 0.48 indicating that CryoPort is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CryoPort 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Turn Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer SPRY or TTRX?

In the previous week, ARS Pharmaceuticals had 3 more articles in the media than Turn Therapeutics. MarketBeat recorded 8 mentions for ARS Pharmaceuticals and 5 mentions for Turn Therapeutics. ARS Pharmaceuticals' average media sentiment score of 0.51 beat Turn Therapeutics' score of 0.48 indicating that ARS Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ARS Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Turn Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer TTRX or OCS?

In the previous week, Turn Therapeutics had 1 more articles in the media than Oculis. MarketBeat recorded 5 mentions for Turn Therapeutics and 4 mentions for Oculis. Oculis' average media sentiment score of 0.78 beat Turn Therapeutics' score of 0.48 indicating that Oculis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Turn Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Oculis 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, IVA or TTRX?

Turn Therapeutics has lower revenue, but higher earnings than Inventiva. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inventiva $5.07M 176.16 -$400.67M N/A N/A Turn Therapeutics N/A N/A -$3.19M -$0.19 N/A

Is IVA or TTRX more profitable?

Company Net Margins Return on Equity Return on Assets Inventiva N/A N/A N/A Turn Therapeutics N/A N/A N/A

Does the media prefer IVA or TTRX?

In the previous week, Turn Therapeutics had 2 more articles in the media than Inventiva. MarketBeat recorded 5 mentions for Turn Therapeutics and 3 mentions for Inventiva. Inventiva's average media sentiment score of 0.62 beat Turn Therapeutics' score of 0.48 indicating that Inventiva is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inventiva 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Turn Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Turn Therapeutics (TTRX) Competitors

$9.47 +0.03 (+0.32%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$9.64 +0.16 (+1.74%)

As of 07/13/2026 07:57 PM Eastern

Compare

TTRX vs. ESPR, CYRX, SPRY, OCS, and IVA

Should you buy Turn Therapeutics stock or one of its competitors? MarketBeat compares Turn Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Turn Therapeutics include Esperion Therapeutics (ESPR), CryoPort (CYRX), ARS Pharmaceuticals (SPRY), Oculis (OCS), and Inventiva (IVA). These companies are all part of the "pharmaceutical products" industry.

How does Turn Therapeutics compare to Esperion Therapeutics?

Turn Therapeutics (NASDAQ:TTRX) and Esperion Therapeutics (NASDAQ:ESPR) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, institutional ownership, risk, dividends, earnings and profitability.

Esperion Therapeutics has a net margin of 0.12% compared to Turn Therapeutics' net margin of 0.00%. Turn Therapeutics' return on equity of 0.00% beat Esperion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Turn Therapeutics	N/A	N/A	N/A
Esperion Therapeutics	0.12%	-0.14%	0.12%

Turn Therapeutics presently has a consensus price target of $8.00, suggesting a potential downside of 15.52%. Esperion Therapeutics has a consensus price target of $5.54, suggesting a potential upside of 73.61%. Given Esperion Therapeutics' higher probable upside, analysts plainly believe Esperion Therapeutics is more favorable than Turn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Turn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Esperion Therapeutics	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

47.4% of Esperion Therapeutics shares are owned by institutional investors. 1.6% of Esperion Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Turn Therapeutics has higher earnings, but lower revenue than Esperion Therapeutics. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Turn Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.19	N/A
Esperion Therapeutics	$403.14M	2.04	-$22.68M	-$0.06	N/A

In the previous week, Esperion Therapeutics had 1 more articles in the media than Turn Therapeutics. MarketBeat recorded 6 mentions for Esperion Therapeutics and 5 mentions for Turn Therapeutics. Esperion Therapeutics' average media sentiment score of 1.22 beat Turn Therapeutics' score of 0.48 indicating that Esperion Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Turn Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Esperion Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Esperion Therapeutics beats Turn Therapeutics on 9 of the 12 factors compared between the two stocks.

How does Turn Therapeutics compare to CryoPort?

CryoPort (NASDAQ:CYRX) and Turn Therapeutics (NASDAQ:TTRX) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations, dividends and media sentiment.

CryoPort has a net margin of 41.57% compared to Turn Therapeutics' net margin of 0.00%. Turn Therapeutics' return on equity of 0.00% beat CryoPort's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CryoPort	41.57%	-7.92%	-4.79%
Turn Therapeutics	N/A	N/A	N/A

CryoPort has higher revenue and earnings than Turn Therapeutics. Turn Therapeutics is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CryoPort	$176.18M	4.49	$78.30M	$1.35	11.64
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.19	N/A

In the previous week, Turn Therapeutics had 2 more articles in the media than CryoPort. MarketBeat recorded 5 mentions for Turn Therapeutics and 3 mentions for CryoPort. CryoPort's average media sentiment score of 1.40 beat Turn Therapeutics' score of 0.48 indicating that CryoPort is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CryoPort	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Turn Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

92.9% of CryoPort shares are held by institutional investors. 9.5% of CryoPort shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

CryoPort presently has a consensus target price of $15.11, indicating a potential downside of 3.81%. Turn Therapeutics has a consensus target price of $8.00, indicating a potential downside of 15.52%. Given CryoPort's stronger consensus rating and higher probable upside, analysts clearly believe CryoPort is more favorable than Turn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CryoPort	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80
Turn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

CryoPort beats Turn Therapeutics on 11 of the 14 factors compared between the two stocks.

How does Turn Therapeutics compare to ARS Pharmaceuticals?

ARS Pharmaceuticals (NASDAQ:SPRY) and Turn Therapeutics (NASDAQ:TTRX) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

68.2% of ARS Pharmaceuticals shares are held by institutional investors. 33.8% of ARS Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, ARS Pharmaceuticals had 3 more articles in the media than Turn Therapeutics. MarketBeat recorded 8 mentions for ARS Pharmaceuticals and 5 mentions for Turn Therapeutics. ARS Pharmaceuticals' average media sentiment score of 0.51 beat Turn Therapeutics' score of 0.48 indicating that ARS Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ARS Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Turn Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ARS Pharmaceuticals currently has a consensus price target of $28.20, suggesting a potential upside of 264.34%. Turn Therapeutics has a consensus price target of $8.00, suggesting a potential downside of 15.52%. Given ARS Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe ARS Pharmaceuticals is more favorable than Turn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Turn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Turn Therapeutics has lower revenue, but higher earnings than ARS Pharmaceuticals. Turn Therapeutics is trading at a lower price-to-earnings ratio than ARS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ARS Pharmaceuticals	$84.28M	9.12	-$171.30M	-$2.01	N/A
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.19	N/A

Turn Therapeutics has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -200.00%. Turn Therapeutics' return on equity of 0.00% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ARS Pharmaceuticals	-200.00%	-153.61%	-60.85%
Turn Therapeutics	N/A	N/A	N/A

Summary

ARS Pharmaceuticals beats Turn Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Turn Therapeutics compare to Oculis?

Turn Therapeutics (NASDAQ:TTRX) and Oculis (NASDAQ:OCS) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, media sentiment, institutional ownership and valuation.

In the previous week, Turn Therapeutics had 1 more articles in the media than Oculis. MarketBeat recorded 5 mentions for Turn Therapeutics and 4 mentions for Oculis. Oculis' average media sentiment score of 0.78 beat Turn Therapeutics' score of 0.48 indicating that Oculis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Turn Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oculis	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

22.3% of Oculis shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Turn Therapeutics presently has a consensus price target of $8.00, indicating a potential downside of 15.52%. Oculis has a consensus price target of $38.33, indicating a potential upside of 191.51%. Given Oculis' stronger consensus rating and higher probable upside, analysts plainly believe Oculis is more favorable than Turn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Turn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Turn Therapeutics has higher earnings, but lower revenue than Oculis. Turn Therapeutics is trading at a lower price-to-earnings ratio than Oculis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.19	N/A
Oculis	$1.45M	525.82	-$119.44M	-$2.13	N/A

Turn Therapeutics has a net margin of 0.00% compared to Oculis' net margin of -8,460.67%. Turn Therapeutics' return on equity of 0.00% beat Oculis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Turn Therapeutics	N/A	N/A	N/A
Oculis	-8,460.67%	-56.78%	-45.62%

Summary

Oculis beats Turn Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Turn Therapeutics compare to Inventiva?

Inventiva (NASDAQ:IVA) and Turn Therapeutics (NASDAQ:TTRX) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations.

In the previous week, Turn Therapeutics had 2 more articles in the media than Inventiva. MarketBeat recorded 5 mentions for Turn Therapeutics and 3 mentions for Inventiva. Inventiva's average media sentiment score of 0.62 beat Turn Therapeutics' score of 0.48 indicating that Inventiva is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inventiva	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Turn Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Turn Therapeutics has lower revenue, but higher earnings than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inventiva	$5.07M	176.16	-$400.67M	N/A	N/A
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.19	N/A

Inventiva currently has a consensus price target of $16.56, suggesting a potential upside of 285.01%. Turn Therapeutics has a consensus price target of $8.00, suggesting a potential downside of 15.52%. Given Inventiva's stronger consensus rating and higher probable upside, analysts plainly believe Inventiva is more favorable than Turn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inventiva	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.10
Turn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

19.1% of Inventiva shares are held by institutional investors. 32.0% of Inventiva shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
Inventiva	N/A	N/A	N/A
Turn Therapeutics	N/A	N/A	N/A

Summary

Inventiva beats Turn Therapeutics on 8 of the 10 factors compared between the two stocks.

Get Turn Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TTRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TTRX vs. The Competition

Export

Metric	Turn Therapeutics	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$281.20M	$931.69M	$5.06B	$12.61B
Dividend Yield	N/A	4.84%	27.48%	8.00%
P/E Ratio	-49.84	1.56	23.70	24.26
Price / Sales	N/A	114.76	146.11	117.88
Price / Cash	N/A	22.05	31.98	49.36
Price / Book	59.19	8.59	12.23	6.29
Net Income	-$3.19M	-$3.66M	$118.20M	$330.66M
7 Day Performance	-2.47%	-2.06%	-1.63%	-1.35%
1 Month Performance	56.53%	0.77%	-1.93%	-0.64%
1 Year Performance	N/A	37.84%	8.97%	19.08%

Turn Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TTRX Turn Therapeutics	0.5948 of 5 stars	$9.47 +0.3%	$8.00 -15.5%	N/A	$281.20M	N/A	N/A	2	High Trading Volume
ESPR Esperion Therapeutics	3.4034 of 5 stars	$3.16 flat	$5.54 +75.3%	+168.2%	$814.31M	$403.14M	N/A	200	Positive News
CYRX CryoPort	3.2382 of 5 stars	$15.49 -2.3%	$15.11 -2.4%	+108.1%	$799.38M	$176.18M	11.47	1,186	News Coverage Gap Up
SPRY ARS Pharmaceuticals	3.2556 of 5 stars	$8.56 +7.8%	$28.20 +229.4%	-56.2%	$788.47M	$84.28M	N/A	90
OCS Oculis	3.0208 of 5 stars	$14.12 +4.4%	$38.33 +171.5%	-27.2%	$784.53M	$1.45M	N/A	2	Positive News Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TTRX) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Turn Therapeutics (TTRX) Competitors

TTRX vs. ESPR, CYRX, SPRY, OCS, and IVA

How does Turn Therapeutics compare to Esperion Therapeutics?

Summary

How does Turn Therapeutics compare to CryoPort?

Summary

How does Turn Therapeutics compare to ARS Pharmaceuticals?

Summary

How does Turn Therapeutics compare to Oculis?

Summary

How does Turn Therapeutics compare to Inventiva?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TTRX vs. The Competition

Turn Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Turn Therapeutics (TTRX) Competitors

TTRX vs. ESPR, CYRX, SPRY, OCS, and IVA

How does Turn Therapeutics compare to Esperion Therapeutics?

Is TTRX or ESPR more profitable?

Do analysts prefer TTRX or ESPR?

Do institutionals & insiders hold more shares of TTRX or ESPR?

Which has stronger valuation & earnings, TTRX or ESPR?

Does the media refer more to TTRX or ESPR?

Summary

How does Turn Therapeutics compare to CryoPort?

Is CYRX or TTRX more profitable?

Which has stronger earnings and valuation, CYRX or TTRX?

Does the media favor CYRX or TTRX?

Do insiders & institutionals hold more shares of CYRX or TTRX?

Do analysts recommend CYRX or TTRX?

Summary

How does Turn Therapeutics compare to ARS Pharmaceuticals?

Do institutionals and insiders hold more shares of SPRY or TTRX?

Does the media prefer SPRY or TTRX?

Do analysts rate SPRY or TTRX?

Which has stronger valuation & earnings, SPRY or TTRX?

Is SPRY or TTRX more profitable?

Summary

How does Turn Therapeutics compare to Oculis?

Does the media prefer TTRX or OCS?

Do insiders & institutionals believe in TTRX or OCS?

Do analysts rate TTRX or OCS?

Which has stronger earnings & valuation, TTRX or OCS?

Is TTRX or OCS more profitable?

Summary

How does Turn Therapeutics compare to Inventiva?

Does the media prefer IVA or TTRX?

Which has higher earnings & valuation, IVA or TTRX?

Do analysts rate IVA or TTRX?

Do insiders and institutionals have more ownership in IVA or TTRX?

Is IVA or TTRX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TTRX vs. The Competition

Turn Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools